The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Pacific Biosciences of California Inc (NASDAQ: PACB) closed the day trading at $1.76 up 1.15% from the previous closing price of $1.74. In other words, the price has increased by $1.15 from its previous closing price. On the day, 9.51 million shares were traded. PACB stock price reached its highest trading level at $1.84 during the session, while it also had its lowest trading level at $1.73.
Ratios:
For a better understanding of PACB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.02 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 11.37 whereas as Long-Term Debt/Eq ratio is at 11.36.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 18 ’25 when Van Oene Mark sold 26,836 shares for $1.31 per share. The transaction valued at 35,182 led to the insider holds 1,920,035 shares of the business.
MARK VAN OENE bought 26,836 shares of PACB for $35,174 on Aug 18 ’25. On May 19 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 5,195 shares for $1.00 each. As a result, the insider received 5,200 and left with 269,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 528652288 and an Enterprise Value of 916138304. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.39 while its Price-to-Book (P/B) ratio in mrq is 8.60. Its current Enterprise Value per Revenue stands at 5.869 whereas that against EBITDA is -4.058.
Stock Price History:
The Beta on a monthly basis for PACB is 2.19, which has changed by -0.111111104 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 31.93%, while the 200-Day Moving Average is calculated to be 29.27%.
Shares Statistics:
Over the past 3-months, PACB traded about 7.25M shares per day on average, while over the past 10 days, PACB traded about 8827410 shares per day. A total of 300.35M shares are outstanding, with a floating share count of 266.29M. Insiders hold about 11.35% of the company’s shares, while institutions hold 56.83% stake in the company. Shares short for PACB as of 1759190400 were 37967832 with a Short Ratio of 5.24, compared to 1756425600 on 37111300. Therefore, it implies a Short% of Shares Outstanding of 37967832 and a Short% of Float of 14.38.
Earnings Estimates
. The current market rating for Pacific Biosciences of California Inc (PACB) reflects the collective analysis of 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.52 and -$0.59 for the fiscal current year, implying an average EPS of -$0.56. EPS for the following year is -$0.5, with 8.0 analysts recommending between -$0.42 and -$0.55.
Revenue Estimates
8 analysts predict $40.25M in revenue for. The current quarter. It ranges from a high estimate of $41.57M to a low estimate of $39.5M. As of. The current estimate, Pacific Biosciences of California Inc’s year-ago sales were $39.97MFor the next quarter, 8 analysts are estimating revenue of $42.86M. There is a high estimate of $44.77M for the next quarter, whereas the lowest estimate is $41M.
A total of 9 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $162.4M, while the lowest revenue estimate was $157.4M, resulting in an average revenue estimate of $160.22M. In the same quarter a year ago, actual revenue was $154.01MBased on 9 analysts’ estimates, the company’s revenue will be $185.76M in the next fiscal year. The high estimate is $201.6M and the low estimate is $177.7M.
